 |
3 Diseases |  |
0 Trials |
|
0 Trials |  |
10 News |  |
- || latanoprost / Generic mfg.
Enrollment closed: Assess the Safety, Tolerability and Efficacy of Latanoprost Liposome for Lower Eyelid Steatoblepharon (clinicaltrials.gov) - Aug 12, 2024
P1, N=40, Active, not recruiting, Sponsor: Peregrine Ophthalmic
Recruiting --> Active, not recruiting
- | latanoprost / Generic mfg.
Trial completion date, Trial primary completion date: Assess the Safety, Tolerability and Efficacy of Latanoprost Liposome for Lower Eyelid Steatoblepharon (clinicaltrials.gov) - Jan 18, 2024
P1, N=40, Recruiting, Sponsor: Peregrine Ophthalmic
Recruiting --> Active, not recruiting Trial completion date: Feb 2024 --> Jun 2024 | Trial primary completion date: Jan 2024 --> May 2024
- | latanoprost / Generic mfg.
Trial completion date: Assess the Safety, Tolerability and Efficacy of Latanoprost Liposome for Lower Eyelid Steatoblepharon (clinicaltrials.gov) - Dec 19, 2023
P1, N=40, Recruiting, Sponsor: Peregrine Ophthalmic
Trial completion date: Feb 2024 --> Jun 2024 | Trial primary completion date: Jan 2024 --> May 2024 Trial completion date: Nov 2023 --> Feb 2024
- || latanoprost / Generic mfg.
New P1 trial: Assess the Safety, Tolerability and Efficacy of Latanoprost Liposome for Lower Eyelid Steatoblepharon (clinicaltrials.gov) - Jul 7, 2023
P1, N=40, Recruiting, Sponsor: Peregrine Ophthalmic
- | latanoprost / Generic mfg.
Journal: Comparison of Soluble and Liposome Encapsulated, Sustained Release Latanoprost for Focal Adipose Reduction. (Pubmed Central) - Nov 4, 2022
Hematoxylin and eosin demonstrated effective reduction in adipocyte volume without histologic evidence of cytolysis or inflammation whereas DOCA caused dermal ulcerations, adipocyte lysis, and increased tissue inflammation. Latanoprost reduced fat volume without inducing cell lysis or inflammation.
- | latanoprost liposomal (POLAT 001) / Avid Bioservices
Trial completion: Open Label Extension of LipoLat-CS202 (clinicaltrials.gov) - Jun 18, 2016
P=N/A, N=17, Completed, Sponsor: Peregrine Ophthalmic
Latanoprost reduced fat volume without inducing cell lysis or inflammation. Active, not recruiting --> Completed
- latanoprost liposomal (POLAT 001) / Avid Bioservices
Enrollment closed, Enrollment change: Open Label Extension of LipoLat-CS202 (clinicaltrials.gov) - Apr 22, 2016
P=N/A, N=17, Active, not recruiting, Sponsor: Peregrine Ophthalmic
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=54 --> 17
- |||| latanoprost liposomal (POLAT 001) / Avid Bioservices
Trial completion: POLAT-001 Compared to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Open-angle Glaucoma (clinicaltrials.gov) - Apr 22, 2016
P2, N=81, Completed, Sponsor: Peregrine Ophthalmic
Recruiting --> Active, not recruiting | N=54 --> 17 Active, not recruiting --> Completed
- ||| latanoprost liposomal (POLAT 001) / Avid Bioservices
Enrollment closed: POLAT-001 Compared to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Open-angle Glaucoma (clinicaltrials.gov) - Feb 24, 2016
P2, N=80, Active, not recruiting, Sponsor: Peregrine Ophthalmic
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| latanoprost liposomal (POLAT 001) / Avid Bioservices
New trial: Open Label Extension of LipoLat-CS202 (clinicaltrials.gov) - Nov 8, 2015
P=N/A, N=54, Recruiting, Sponsor: Peregrine Ophthalmic
- latanoprost liposomal (POLAT 001) / Avid Bioservices
Enrollment open: POLAT-001 Compared to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Open-angle Glaucoma (clinicaltrials.gov) - Jul 9, 2015
P2, N=81, Recruiting, Sponsor: Peregrine Ophthalmic
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | latanoprost liposomal (POLAT 001) / Avid Bioservices
New P2 trial: POLAT-001 Compared to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Open-angle Glaucoma (clinicaltrials.gov) - Jun 9, 2015
P2, N=81, Not yet recruiting, Sponsor: Peregrine Ophthalmic
- latanoprost liposomal (POLAT 001) / Avid Bioservices
New P1/2 trial: Safety and Efficacy of Liposomal Latanoprost in Ocular Hypertension (clinicaltrials.gov) - Nov 17, 2013
P1/2, N=6, Completed, Sponsor: Singapore Eye Research Institute